



11755 Wilshire Boulevard, Suite 2000  
Los Angeles, California 90025  
tel 310.883.1300 fax 310.998.8553  
[www.abraxisbio.com](http://www.abraxisbio.com)

April 30, 2008

Minnesota Board of Pharmacy  
2829 University Ave. SE, Suite 530  
Minneapolis, MN 55414-3253

**Re: Wholesale Drug Distributor Disclosures**

Ladies and Gentlemen:

Abraxis BioScience, LLC ("Abraxis") is a fully integrated biotechnology company dedicated to discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. Abraxis' currently only approved product is available by prescription to the residents of Minnesota.

**Reporting Requirements**

MINN. STAT. § 151.47(f) requires wholesale drug distributors to file with the Minnesota Board of Pharmacy an annual report identifying "all payments, honoraria, reimbursement or other compensation authorized under section 151.461, clauses (3) to (5), paid to practitioners in Minnesota during the preceding calendar year." Additionally, the Minnesota law requires wholesale drug distributors to identify "the nature and value of any payments totaling \$100 or more, to a particular practitioner during the year, and shall identify the practitioner." This report is due annually by May 1st.

**Reports Filed with the Minnesota Board of Pharmacy for the 2007 Reporting Year**

In an effort to complete the filing of the 2007 reports, Abraxis underwent an examination of all readily available data regarding payments and other compensation to healthcare practitioners in Minnesota. The relevant data from this data set has been compiled and the reports for 2007 year were completed on the form supplied by the Minnesota Board of Pharmacy. This report is enclosed with this letter.

Consistent with MINN. STAT. § 151.47, certain expenditures which are exempt from disclosure were not included. These expenditures are professional samples of a drug intended for free distribution to patients; items with a total combined retail value, in any calendar year, of not more than \$50; publications and educational materials; or salaries or other benefits paid to employees.

Abraxis has made every effort to disclose all available data in the format required by MINN. STAT. § 151.47 and the Minnesota Board of Pharmacy. However, as noted in our previous

Abraxis BioScience

Minnesota Wholesale Drug Distributor Disclosures, MINN. STAT. § 151.47

April 30, 2008

correspondence, Abraxis is aware that a more robust collection and reporting process may need to be institutionalized in order to meet all reporting requirements. Abraxis has implemented policies to ensure that the required data is collected and reported. However, Abraxis is continuing to work on improving the process through evaluating, developing and implementing new collection processes. Abraxis is taking necessary steps to ensure compliance with all requirements of MINN. STAT. § 151.47.

Abraxis' product Abraxane®, is co-promoted in the United States by AstraZeneca UK Limited and Abraxis. Due to the nature of the co-promotion agreement, any spend incurred by AstraZeneca and required under the Minnesota statute for the relevant reporting period should be reported by AstraZeneca.

Abraxis was formed in November 2007 as a result of a spin-off from APP Pharmaceuticals, Inc. As a result of the spin-off, new licenses and/or updates were required for both Abraxis and APP Pharmaceuticals in Minnesota and elsewhere. Abraxis recently applied for a Minnesota wholesale distributor license and is still waiting for that number. However, all of Abraxis' products are distributed in North America, including Minnesota, through APP Pharmaceuticals pursuant to a written agreement. APP Pharmaceuticals' Minnesota license number is 361121.

We will make ourselves available at a time that is convenient for you if you would like to discuss this matter further. Please contact me if you have any questions or if you would like to schedule a meeting or conference call.

Sincerely,



Charles C. Kim, Esq.  
Acting General Counsel

Enclosure